Headlines from across medwireNews
21-04-2017 | Oncology | News | Article
Caution needed when using PFS as an OS surrogate in immunotherapy trials
In phase II and III trials of oncologic immunotherapeutic agents, treatment effect sizes are on average larger for progression-free survival than for overall survival, find researchers who question the value of using progression-free survival as a surrogate for overall survival in such trials.
Beyond the news
medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.
Click through to read the full reports of the latest research.
Highlights from the 1st conference of the European Academy of Neurology in Berlin, Germany.
Click through to read research news from the conference.
medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make medwireNews.com your preferred medical news resource.
Salmon_avocado_nuts/© Yulia Furman / Fotolia, migraine_headache3, surgery11, ESMO 2016 flags_enhanced/© Lynda Williams, Children with medical team/© Christopher Futcher, Brandenburg Gate/© Nikada/iStock, Lucy Piper, Lynda Williams, Eleanor McDermid, Shreeya Nanda, Claire Barnard, Alison Chapman, Kamran Ahmad